Projektbeschreibung
Antibiotikaresistenz: Bald neue Arzneimittel in klinischen Studien?
Gramnegative Bakterien haben eine Außenmembran, die keine Antibiotika durchlässt. Die steigende Mehrfachresistenz gramnegativer Bakterien wächst sich zu einem immensen Problem für die öffentliche Gesundheit aus. Das EU-finanzierte Projekt GNA NOW will sich dem stellen. Im Rahmen des neuen EU-Programms Antimicrobial Resistance Accelerator (AMR) wollen Expertengruppen aus Wissenschaft und Industrie in den nächsten sechs Jahren die vielversprechendsten antibiotischen Verbindungen finden, testen und eine Handvoll von ihnen auch in klinische Studien übertragen.
Ziel
AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics.
Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Aufforderung zur Vorschlagseinreichung
H2020-JTI-IMI2-2018-16-single-stage
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
RIA - Research and Innovation actionKoordinator
3521 AL Utrecht
Niederlande
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).